Investigating how eosinophils contribute to blood clotting and artery disease in people with LNK deficiency
Official title: The role of eosinophil in thrombosis and atherosclerosis in LNK deficiency
Funded at Columbia University Health Sciences · NIH-10999452 · Data updated 2026-11-12
This study is looking at how a type of white blood cell called eosinophils might play a role in blood clots and artery disease, especially in people with a specific genetic condition, to help find new ways to prevent heart problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $562,766 |
| NIH project number | 5R01HL168392-02 |
| Project ID | NIH-10999452 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with LNK deficiency, particularly those from African American, European, or Latin American backgrounds.
✕Less likely to help
Patients without LNK deficiency or those not affected by atherothrombotic cardiovascular disease may not benefit from this research.
What this research studies
This research explores the role of eosinophils, a type of white blood cell, in the development of blood clots and artery disease, particularly in individuals with a specific genetic variant known as LNK deficiency. The study utilizes mouse models to understand how this deficiency affects blood cell behavior and contributes to cardiovascular issues. By examining the interactions between eosinophils, neutrophils, and platelets, the research aims to uncover new therapeutic targets for preventing atherothrombotic cardiovascular disease. Patients may benefit from insights that could lead to novel treatments tailored to their genetic profiles.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that specifically target eosinophils to reduce the risk of blood clots and artery disease.
How similar studies have gone: Other research has shown promising results in understanding the role of eosinophils in cardiovascular diseases, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Wang, Nan — Columbia University Health Sciences
- Study coordinator: Wang, Nan
Related research
Other NIH-funded projects on the same topics.
-
Gut bacteria and heart disease: promising new pathways to reduce atherosclerosis and clots
A researchers team is studying how certain gut bacteria make chemicals that may influence heart disease and clotting, with findings that could lead to new ways to prevent or treat these conditions.
-
How eosinophils may drive clots and artery disease when LNK is reduced
This research will learn whether eosinophils make blood clots and artery disease worse in people who carry a common LNK/SH2B3 genetic change that raises heart attack and stroke risk.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
PFAS may speed up artery disease by changing bile acids
Aims to see if PFAS chemicals make cholesterol rise and arteries more likely to harden, using a human-similar mouse model to understand how this could affect people.
-
IgE antibodies to alpha-gal and heart disease in mice and people
A study to understand how specific IgE antibodies against alpha-gal might influence the development and severity of atherosclerosis in humans and mouse models.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.